Biotricity, Inc. (BTCY) reported revenue of $4.28 million for the quarter ended June 30, 2026. This figure rose from $3.87 million in the prior-year period. Technology fees primarily drove the revenue growth. Operating cash flow turned positive at $507,227 for the quarter.
Despite these gains, the company issued a going concern warning in its latest SEC filing. Biotricity reported a working capital deficiency of $31.75 million. Total liabilities reached $39.72 million against $6.02 million in total assets. Management stated the company needs additional debt or equity financing to operate for the next 12 months.